© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Crescent Biopharma, Inc. (CBIO) shows an Average True Range (ATR) of 0.97 and an Enterprise Value of 19.42M. Its average trading volume over the past 3 months is 178.12K, indicating liquidity. These fundamental metrics provide insight into CBIO's underlying financial health and market activity.
| ATR | 0.97 |
| Enterprise Value | 19.42M |
| Avg Vol (3 Months) | 178.12K |
| Avg Vol (10 Days) | 229.1K |
Crescent Biopharma, Inc. (CBIO) technical indicators as of March 26, 2026: the SMA 20 is 20.06%, SMA 50 at 8.73%, and SMA 200 at -10.65%. The RSI 14 value is 62.01, suggesting its current momentum. These technical analysis signals help assess CBIO's price trends and potential future movements.
| SMA 20 | 20.06% |
| SMA 50 | 8.73% |
| SMA 200 | -10.65% |
| RSI 14 | 62.01 |
Crescent Biopharma, Inc. (CBIO) stock performance overview as of March 26, 2026: The 52-week high is $21.4 (currently -57.52% below), and the 52-week low is $8.72 (currently 41.57% above). Over the past year, CBIO's performance is -44.57%, compared to the S&P 500's 14.34% change.
| 52-Week High | 21.4 |
| 52-Week High Chg | -57.52% |
| 52-Week Low | 8.72 |
| 52-Week Low Chg | +41.57% |
| S&P 500 52-Week Chg | 14.34% |
According to market data, Crescent Biopharma, Inc. (CBIO) stock's recent performance metrics show that over the last month, CBIO is 11.93%, with a Year-to-Date (YTD) performance of 17.88%. Over the past year, the stock has seen a -44.57% change. These figures summarize CBIO's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 12.51 | 13.51 | 14.71 | 16.35 | 21.4 | 14.71 |
| Low | 10.16 | 9.98 | 8.72 | 8.72 | 8.72 | 8.72 |
| Performance | +27.32% | +11.93% | +11.48% | +5.91% | -44.57% | +17.88% |
According to current financial data, CBIO stock's P/E (TTM) ratio is -8.52, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.23. Key valuation ratios for CBIO, including P/S (7.68), P/B (5.92), and P/FCF (-13.60), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | CBIO | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -8.52 | -1.23 | -5.16 | 32.59 |
| P/S (TTM) | 7.68 | 3.71 | 464.92 | 5.98 |
| P/B (TTM) | 5.92 | 7.62 | 4.77 | 4.62 |
| P/FCF (TTM) | -13.6 | -13.15 | -221.03 | 32.15 |